Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BookCitation
.... 14.5 BookPartCitation
.... 14.6 CertaintyOfEvidence
.... 14.7 Classification
.... 14.8 CohortDefinition
.... 14.9 Comment
.... 14.10 ComparativeBaselineMeasureEvidence
.... 14.11 ComparativeEvidence
.... 14.12 ComparativeEvidenceReport
.... 14.13 ComparativeEvidenceReportSubject
.... 14.14 ComparativeEvidenceSynthesisReport
.... 14.15 ComparativeParticipantFlowEvidence
.... 14.16 ComparatorDefinition
.... 14.17 ComparatorGroup
.... 14.18 ComparatorOnlyEvidence
.... 14.19 Comparison
.... 14.20 CompositeRating
.... 14.21 ConceptualCohortDefinition
.... 14.22 DatabaseCitation
.... 14.23 DatabaseEntryCitation
.... 14.24 DatasetCitation
.... 14.25 DateAsRating
.... 14.26 DichotomousPatientImportantOutcome
.... 14.27 EndpointAnalysisPlan
.... 14.28 EvidenceList
.... 14.29 EvidenceMap
.... 14.30 EvidenceMeasureReportPackage
.... 14.31 EvidenceReport
.... 14.32 EvidenceReportPackage
.... 14.33 EvidenceReportSubject
.... 14.34 EvidenceSynthesisEvidence
.... 14.35 EvidenceTableReportPackage
.... 14.36 ExposureDefinition
.... 14.37 ExposureGroup
.... 14.38 GroupAssignment
.... 14.39 GroupR6
.... 14.40 Guideline
.... 14.41 InterventionOnlyEvidence
.... 14.42 JournalArticleCitation
.... 14.43 M11Report
.... 14.44 M11ResearchStudy
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 OutcomeMeasureSynthesisReport
.... 14.58 ParticipantFlowEvidence
.... 14.59 ParticipantFlowEvidenceVariable
.... 14.60 ParticipantFlowReport
.... 14.61 PreprintCitation
.... 14.62 Rating
.... 14.63 Recommendation
.... 14.64 RecommendationAction
.... 14.65 RecommendationEligibilityCriteria
.... 14.66 RecommendationJustification
.... 14.67 RecommendationPlan
.... 14.68 ResearchStudyDataDictionary
.... 14.69 RiskOfBias
.... 14.70 SearchResults
.... 14.71 SearchStrategy
.... 14.72 SingleStudyEvidence
.... 14.73 SoaPlanDefinition
.... 14.74 SoftwareCitation
.... 14.75 StatisticModel
.... 14.76 StudyEligibilityCriteria
.... 14.77 StudyGroup
.... 14.78 SummaryOfFindings
.... 14.79 SummaryOfNetEffect
.... 14.80 SystematicReview
.... 14.81 SystematicReviewEligibilityCriteria
.... 14.82 SystematicReviewExcludedStudies
.... 14.83 SystematicReviewIncludedStudies
.... 14.84 VariableDefinition
.... 14.85 WebPageCitation
.... 14.86 ArtifactAssessmentCompared
.... 14.87 ArtifactAssessmentDateAsRating
.... 14.88 CharacteristicTiming
.... 14.89 EvidenceVariableClassifier
.... 14.90 EvidenceVariableConditional
.... 14.91 EvidenceVariableConstraint
.... 14.92 EvidenceVariableDataCleaning
.... 14.93 EvidenceVariableDataStorage
.... 14.94 EvidenceVariableMissingData
.... 14.95 EvidenceVariablePeriod
.... 14.96 ResearchStudyEstimand
.... 14.97 ResearchStudyExcludedStudy
.... 14.98 ResearchStudyIncludedStudy
.... 14.99 ResearchStudyNumberOfStudiesIdentified
.... 14.100 ResearchStudyNumberOfStudiesIncluded
.... 14.101 ResearchStudyResultAsComposition
.... 14.102 ResearchStudySaeReportingMethod
.... 14.103 ResearchStudySearchStrategy
.... 14.104 ResearchStudySponsorConfidentialityStatement
.... 14.105 ResearchStudyStudyAmendment
.... 14.106 ResearchStudySystematicReviewEligibilityCriteria
.... 14.107 StatisticModelExpression
.... 14.108 StatisticModelIncludeIf
.... 14.109 Evidence Report Contributor Role Value Set
.... 14.110 Evidence Variable Role Subtype Value Set
.... 14.111 Recommendation Justification Classifier Codes Value Set
.... 14.112 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.113 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.114 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.115 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.116 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.117 179899
.... 14.118 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.119 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.120 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.121 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.122 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.123 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.124 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.125 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.126 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.127 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.128 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.129 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.130 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.131 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.132 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.133 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.134 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.135 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.136 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.137 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.138 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.139 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.140 27979893 6. Glycemic Targets.
.... 14.141 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.142 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.143 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.144 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.145 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.146 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.147 30467172 Finding my inner Wonder Woman.
.... 14.148 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.149 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.150 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.151 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.152 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.153 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.154 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.155 Adults with type 2 diabetes
.... 14.156 Adults with type 2 diabetes and CVD and CKD
.... 14.157 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.158 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.159 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.160 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.161 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.162 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.163 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.164 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.165 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.166 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.167 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.168 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.169 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.170 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.171 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.172 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.173 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.174 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.175 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.176 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.177 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.178 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.179 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.180 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.181 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.182 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.183 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.184 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.185 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.186 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.187 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.188 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.189 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.190 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.191 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.192 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.193 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.194 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.195 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.196 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.197 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.198 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.199 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.200 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.201 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.202 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.203 ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.204 ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.205 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.206 ComparatorGroup: Obese patients ≥ 18 years old without bariatric surgery
.... 14.207 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.208 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.209 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.210 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.211 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.212 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.213 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.214 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.215 Computable_Publishing_LLC
.... 14.216 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.217 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.218 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.219 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.220 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.221 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.222 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.223 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.224 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.225 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.226 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.227 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.228 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.229 ConceptualCohortDefinition: Nonfatal stroke
.... 14.230 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.231 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.232 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.233 ConceptualCohortDefinition: Severe obesity
.... 14.234 ConceptualCohortDefinition: T1DM or T2DM
.... 14.235 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.236 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.237 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.238 ConceptualCohortDefinition_Cardiovascular_event
.... 14.239 COVID_19PneumoniaHospitalizedAdult
.... 14.240 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.241 DatabaseCitation: Citation for FEvIR Platform
.... 14.242 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.243 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.244 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.245 Delany-Moretlwe 2022 clinical trial
.... 14.246 Diabetes treatment medication
.... 14.247 EBMImplementationGuideProfile Value Set
.... 14.248 Eligibility criteria for NMA_Diabetes
.... 14.249 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.250 EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.251 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.252 EvidenceMap: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.253 EvidenceReportSectionCode Value Set
.... 14.254 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.255 EvidenceVariableRoleSubtype Value Set
.... 14.256 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.257 ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.258 ExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.259 ExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.260 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.261 ExposureVariable: Age (as continuous variable)
.... 14.262 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.263 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.264 ExposureVariable: pht013093.v1.p1 RACE
.... 14.265 ExposureVariable: pht013093.v1.p1 SEX
.... 14.266 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.267 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.268 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.269 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.270 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.271 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.272 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.273 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.274 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.275 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.276 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.277 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.278 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.279 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.280 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.281 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.282 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.283 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.284 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.285 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.286 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.287 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.288 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.289 Investigator
.... 14.290 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.291 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.292 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.293 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.294 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.295 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.296 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.297 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.298 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.299 M11 Report Template Instructions
.... 14.300 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.301 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.302 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.303 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.304 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.305 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.306 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.307 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.308 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.309 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.310 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.311 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.312 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.313 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.314 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.315 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.316 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.317 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.318 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.319 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.320 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.321 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.322 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.323 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.324 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.325 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.326 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.327 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.328 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.329 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.330 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.331 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.332 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.333 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.334 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.335 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.336 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.337 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.338 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.339 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.340 Mortality at 14 days
.... 14.341 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.342 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.343 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.344 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.345 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.346 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.347 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.348 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.349 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.350 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.351 NHANES LBDGLUSI: Fasting Glucose (mmol/L) Variable Definition
.... 14.352 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.353 NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition
.... 14.354 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.355 NHANES SEQN Respondent Sequence Number
.... 14.356 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.357 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight) Variable Definition
.... 14.358 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.359 Organ support-free days
.... 14.360 Outcome Importance Rating 100 of All-cause mortality
.... 14.361 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.362 Outcome Importance Rating 5 of New onset depression
.... 14.363 Outcome Importance Rating 5 of Remission of diabetes
.... 14.364 Outcome Importance Rating 5 of Treatment with opioids
.... 14.365 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.366 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.367 OutcomeDefinition: All-cause mortality
.... 14.368 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.369 OutcomeDefinition: Body weight
.... 14.370 OutcomeDefinition: Cardiovascular mortality
.... 14.371 OutcomeDefinition: Diabetes in remission
.... 14.372 OutcomeDefinition: Diabetic ketoacidosis
.... 14.373 OutcomeDefinition: End-stage kidney disease
.... 14.374 OutcomeDefinition: Genital infection
.... 14.375 OutcomeDefinition: HbA1c at 12 months
.... 14.376 OutcomeDefinition: HbA1c at 24 months
.... 14.377 OutcomeDefinition: HbA1c at 36 months
.... 14.378 OutcomeDefinition: HbA1c at 6 months
.... 14.379 OutcomeDefinition: HbA1c at 60 months
.... 14.380 OutcomeDefinition: Health-related quality of life
.... 14.381 OutcomeDefinition: Heart failure
.... 14.382 OutcomeDefinition: Mortality at 14 days
.... 14.383 OutcomeDefinition: New onset depression
.... 14.384 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.385 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.386 OutcomeDefinition: Nonfatal stroke
.... 14.387 OutcomeDefinition: Serious hyperglycaemia
.... 14.388 OutcomeDefinition: Severe gastrointestinal events
.... 14.389 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.390 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.391 OutcomeVariable: HbA1c at 12 months
.... 14.392 OutcomeVariable: HbA1c at 24 months
.... 14.393 OutcomeVariable: HbA1c at 36 months
.... 14.394 OutcomeVariable: HbA1c at 6 months
.... 14.395 OutcomeVariable: HbA1c at 60 months
.... 14.396 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.397 OutcomeVariable: New onset depression
.... 14.398 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.399 OutcomeVariable: Remission of diabetes
.... 14.400 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.401 OutcomeVariable_All_cause_mortality
.... 14.402 OutcomeVariable_Treatment_with_opioids
.... 14.403 Participant Flow Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.404 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.405 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.406 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.407 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.408 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.409 ParticipantFlowMeasure: Exclusion from analysis
.... 14.410 ParticipantFlowMeasure: Inclusion in analysis
.... 14.411 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.412 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.413 Placebo
.... 14.414 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.415 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.416 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.417 Recommendation Justification Code System
.... 14.418 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.419 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.420 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.421 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.422 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.423 Remdesivir
.... 14.424 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.425 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.426 Risk Of Bias Type Value Set
.... 14.427 Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide
.... 14.428 Search Strategy for NMA_Diabetes
.... 14.429 SearchResults: PubMed search for Wonder Woman
.... 14.430 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.431 SearchStrategy: PubMed search for Wonder Woman
.... 14.432 SearchStrategyCharacteristicCode Value Set
.... 14.433 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.434 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.435 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.436 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.437 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.438 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.439 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.440 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.441 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.442 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.443 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.444 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.445 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.446 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.447 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.448 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.449 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.450 Therapeutic-dose anticoagulation with heparin
.... 14.451 WebPageCitation: A HEvKA Update Summary